type 2 diabetes mellitus with nonalcoholic fatty liver disease
Conditions
Interventions
semeglutide group:semeglutide
empagliflozin group:empagliflozin
semeglutide add on empagliflozin group:semeglutide add on empagliflozin
Sponsors
Xiamen Humanity Hospital, Fujian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.type 2 diabetes mellitus 2.fatty liver 3.overweight or obesity(body mass index more than 24kg/m2) 4.patients older than 14 years old 5.patients who had not used glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter 2 inhibitors within 4 weeks. 6.voluntarily accept this study, and sign the participants informed consent.
Exclusion criteria
Exclusion criteria: 1.gestational diabetes mellitus, type 1 diabetes mellitus, other types of diabetes mellitus 2.patients who had used thiazolidinediones 3.patients with cardiac, hepatic or renal insufficiency 4.other types of hepatitis 5.patients with cerebral stroke, malignant tumor or pancreatitis 6.patients with pregnancy or lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree of fatty liver;level of glucagon;level of free fatty acid;Glycated hemoglobin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver stiffness;Nonalcoholic fatty liver fibrosis score;Fibrosis 4 Score;fasting insulin;fasting glucose;25-hydroxyvitamin D3;interleukin-6;blood pressure;body mass index;ferritin;CAP;weight loss achieving at least 7%;adiponectin; | — |
Countries
China
Contacts
Public ContactTian Jian-qing
Department of Endocrinology, Xiamen Humanity Hospital, Fujian Medical University
Outcome results
None listed